Last reviewed · How we verify
RYZ101 Dose Level 3
At a glance
| Generic name | RYZ101 Dose Level 3 |
|---|---|
| Sponsor | RayzeBio, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. (PHASE1, PHASE2)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (PHASE1)
- A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RYZ101 Dose Level 3 CI brief — competitive landscape report
- RYZ101 Dose Level 3 updates RSS · CI watch RSS
- RayzeBio, Inc. portfolio CI